A cell therapy biotech finds a delivery partner; FDA removes clinical hold on Ocugen's Covid candidate
Umoja Biopharma will pair its so-called VivoVec particles with Lupagen’s Side CAR-T delivery system to target certain cancers, the companies said Monday.
As part of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
